简介:目的探究2型糖尿病合并冠心病的临床特征,重点研究2型糖尿病合并冠心病的治疗途径。方法随机选取本院三年来确诊的2型糖尿病患者,共70例。随机分为两组,一组为2型糖尿病合并冠心病组,35人;另一组为单纯的2型糖尿病组,35人。记录两组患者的基本资料、体征等与分析有关的数据,除血压外各项数据无统计学差异。结果两组患者的基本资料和各项体征,除血压外如体重、血清总胆固醇等各项数值通过比较没有太明显的差异(P〉0.05),FBG、TG、HLD、LDL、HbAlc数值具有统计学差异,P〈0.05。结论2型糖尿病合并冠心病的病因很多,所以,2型糖尿病合并冠心病的患者在临床治疗中应从血压血脂的控制、血尿酸的检查进行入手。
简介:目的探讨CHA2DS2-VASc评分与射频消融术前心房颤动患者左心房(leftatrium,LA)/左心耳(leftatrialap-pendage,LAA)发生血栓事件的关系。方法根据术前食管超声心动图检查结果,将接受射频消融术的心房颤动患者分为LA/LAA血栓形成组(n=21)与血栓未形成组(n=21),对照分析CHA2DS2-VASc及CHADS2评分对血栓事件的预测价值。结果血栓形成组21例(3.8%)患者血栓均位于LAA,低危组(0分)、中危组(1分)、高危组(≥2分)间,LA/LAA血栓事件发生率无统计学意义(P>0.05),但≥3分患者血栓形成明显多于<2分(P<0.01)。血栓形成组CHA2DS2-VASc评分、CHADS2评分、左心房内径(LAD)显著高于血栓未形成组外,其余临床因素间比较均无统计学意义。多元Logistic回归分析显示:LAD、CHA2DS2-VASc评分是LA/LAA血栓形成的独立危险因素(OR=0.81、0.89,P<0.05)。结论无论CHA2DS2-VASc评分的高低,所有房颤患者射频消融术前均需接受食管超声心动图探查,LAD越大、CHA2DS2-VASc评分越高,LA/LAA血栓事件发生可能性越高。
简介:目的探讨广谱氯离子通道阻滞剂4,4’-二异硫氰基芪-2,2’-二磺酸(DIDS)对大鼠缺血再灌注损伤心肌细胞凋亡的影响及其机制。方法雄性SD大鼠36只随机分为3组:缺血再灌注组(A组)、DIDS处理组(B组)和LY294002预处理组(C组)。伊文兰和TTC染色测定心肌梗死范围,TUNEL方法定性和定量检测心肌细胞凋亡指数,Westernblot测定蛋白激酶B(Akt)的表达。结果与A组比较,B组心肌梗死范围和心肌细胞凋亡指数明显降低[(38.8±7.7)%”(54.2±10.8)%,(8.9±1.8)%”(17.6±3.5)%.P〈0.01];磷酸化Akt表达水平明显增加(P〈0.01)。与A组比较,C组梗死面积、凋亡指数无明显减小,磷酸化Akt水平无明显变化(P〉0.05)。结论DIDS能够抑制大鼠缺血再灌注所致的心肌细胞损伤,可能是通过信号分子磷脂酰肌酶三羟基激酶/Akt的调节。
简介:BackgroundAcutecoronarysyndrome(ACS)isaleadingcauseofmortalityandmorbidityworldwide,whichcomprisesunstableangina(UA)andacutemyocardialinfarction(AMI),andtheinvestigationofbiologicalmarkerstoassessthosemostatriskofrecurrentcardiovasculareventsisnecessary.MethodsSixty-sixhealthycontrolpeopleand67casesofUApatientswereenrolledinGuangdonggeneralhospital.Enzymelinkedimmunosorbentassay(ELISA)wasusedtodetectthelevelofplasmaACTG2.Thereceiveroperatingcharacteristiccurve(ROC)wasusedtoanalyzethepredictionvalueofACTG2forUA.AccordingtotheaveragelevelofplasmaACTG2inUApatients,UApatientsweredividedintothelowACTG2group(
简介:BackgroundNowadays,thestudiesmainlyfocusonthefunctionofdecreasingtheinflammatoryfactorandimprovingthefunctionsofendothelium,buttheeffectsofstatinsonventricularremodelingarerarelystudied.MethodsThe2-kindey,1-cliphypertensiverats(2K1C,Goldblatt)werepreparedwithSprague-Dawley(SD)rat.SDratswererandomlydividedintothreegroups:controlrats,hypertensiveratsandhypertensiveratstreatedwithatorvastatin(2mg·kg-1·d-1).After6weeks,systolicbloodpressure(SBP)wasmeasuredusingthetail-cuffmethod.TheplasmaconcentrationofangiotensinⅡandreninactivityweredeterminedbyradioimmunoassay.Theheartweight,theratioofleftventricularweightandbodyweightwascalculated.ResultsTheplasmaconcentrationofangiotensinⅡ(106.4±7.8)ng/Landreninactivity(20.6±2.4)ng/Lweresignificantlyincreaedinhypertensiveratscomparedwithnormalrats[(72.3±5.4)ng/Land(12.5±3.7)ng/L](P<0.01).Theheartweight(1.46±0.09)g,theratio3.54±0.19(×10-3)ofleftventricularweightandbodyweightinhypertensiveratswereobviouslyhigherthanthatinnormalrats[(0.98±0.07)gand(2.28±0.06)×10-3](P<0.01).Aftertreatmentwithatorvastatin,theplasmaconcentrationofangiotensinⅡ(68.3±6.9)ng/Landreninactivity(8.7±2.3)ng/L,heartweight(1.05±0.04)g,theratio2.36±0.07(×10-3)aboveweredecreasedsignificantly,therewerenodifferencebetweenthegroupofhypertensiveratsandthenormal.ConclusionsAtorvastatincandecreasetheratioofleftventricularweightandbodyweightandhastheeffectsoncardiovascularremodelinginhypertensiverats.
简介:ObjectivesTostudyclinicalandcoronaryangiographicfindingsinpatientswithbothcoronaryheartdiseases(CHD)andtype2diabetesmellitus(T2DM).Methods215patientswithCHDconfirmedbycoronaryangiographywereinvolvedinthisstudy.Thepatientsweredividedintotwogroups:74CHDpatientswithT2DM(meanage64.7±8.2years,male/female47/27),and141CHDpatientswithoutT2DM(meanage66.2±9.2years,male/female100/41).Theclinicalfeaturesandthedatafromselectivecoronaryangiographieswerecomparedbetweentype2diabeticandnon-diabeticCHDpatients.ResultsComparedtonon-diabeticCHDpatients,thepatientswithbothCHDandT2DMsufferedmorefromacutemyocardialinfarction,silentischemiaandseverearrhythmias(P<0.01,P<0.05),andhadhigherserumtriglyceridesandapo-lipoproteinB,alongwithincreasedserumuricacid(P<0.01,P<0.05),increasedleftventricularenddiastolicdiameter(P<0.01),anddecreasedleftventricularejectionfraction(P<0.001).Comparedtonon-diabeticCHDpatients,thepatientswithbothCHDandT2DMsufferedmorefromtriplevesseldisease(P<0.01),severecoronaryarterystenosis,completeocclusionsanddiffuselesions(P<0.001).ConclusionsSevereclinicalmanifestation,leftventriculardysfunction,diffuseorcomplicatedlesionsofcoronaryarteriesweremorecommoninpatientswithbothCHDandT2DM,itsuggeststhatthetype2diabeticCHDpatientshavepoorprognosis.
简介:Themyocardialprotectionaffordedbyischemicpreconditioning(IPC)canalleviateischemia-reperfusioninjuryinnormalratheart.However,thismyocardialprotectionisseldomstudiedinthetype2diabeticratwithmyocardialischemiadisease.Inthisstudy,weaimedtoevaluatetheeffectsofATP-sensitivepotassiumchannels(KATPchannels)onIPCintheisolatedtype2diabeticratheartandtheroleofthesulfonylureagliclazide.MethodsStreptozotocin(STZ)-inducedtype2diabeticmaleWistarratswithorwithoutgliclazide(64mg/kgbodyweight,orally)andage-matchednon-diabeticcontrolratswereusedforallstudies.TheisolatedheartswereperfusedwithLangendorff'ssystemundertheconstantflow,pressureandtemperatureconditionswithKreb's-Henseleitsolution(K-H).After5minutesofbalanceperfusion,theseratswererandomlydividedintosixgroups:non-diabeticcontrolratswithoutIPC(CIR);non-diabeticcontrolratswithIPC(CIP);diabeticratswithoutIPC(DIR);diabeticratswithIPC(DIP);gliclazide-treateddiabeticratswithoutIPC(GIR);andgliclazide-treateddiabeticratswithIPC(GIP).GroupsCIR,DIR,andGIRweresubjectedto30-minglobalischemiaand60-minreperfusionforinductionofischemia/reperfusioninjury.GroupsCIP,DIP,andGIPweregiventhreecyclesof5-minischemiaand5-minreperfusionasIPC,andthenischemia/reperfusioninjuryprogramwasimplemented.Extentofischemia/reperfusioninjurywasmeasuredintermsofthereleaseoflactatedehydrogenase(LDH),creatinekinase(CK),andcreatinkinase-MB(CKMB)incoronaryeffluent.Afterperfusion,Kir6.2andSUR2AmRNAexpressionsinthemyocardialtissuewerecharacterizedbyfluorescentquantitativereal-timePCRmethod,andKir6.2andSUR2Aproteinexpressionswereassessedbyimmunohistochemistry.ResultInnon-diabeticcontrolrats,thereleaseofLDH,CK,andCK-MBincoronaryeffluentmarkedlydecreasedwithIPCcomparedwithNo-IPC(P<0.05),butnotindiabeticrats.However,ingliclazide-treateddiabeticrats,IPC-induceddecreaseintherele
简介:ObjectivesTheeffectsofcarvediloloncalciumcurrent(ICa)wereinvestigatedinisolatedadultratventricularmyocytes.MethodsICawasrecordedbyusingwhole-cellpatch-clamprecordingtechnique.ResultsCarvedilolreversiblyinhibitedICainaconcentration-dependentmanner,carvedilolat0.1,0.3,1and10μmol/LintheextracellularsolutiondecreasedpeakICaby1.52%,18.04%,37.34%and72.18%,respectively.Thesteady-stateinactivationcurveofICawasshiftedtomorenegativepotentials,whiletheactivationcurvewasnotaltered.Therecoveryfrominactivationwasshiftedtorightdirection,itcouldnotberecoveredcompletely.Inaddition,Pretreatmentofventricularmyocyteswithprazosinandpropranololcouldn'tblockthecarvedilol-inducedreductionofICa.ConclusionsCarvedilolinhibitsICainadultratventricularmyocytesbymechanismsinvolvingpreferentialinteractionwiththeinactivatedstateofcalciumchannel.
简介:目的:探讨2型糖尿病(T2DM)合并高血压与否对脂代谢、微血管病变、血液流变学的影响。方法:192例T2DM患者被分为血压正常组(A组,96例)和合并高血压组(B组,100例),对两组的一般情况、血压、脂代谢、微血管损害及血液流变学情况进行比较分析。结果:B组的血压(148±24)mmHg/(86±15)mmHg、胆固醇(6.0±0.9)mmol/L、血肌酐(70±21.1)μmol/L、血尿酸(343±81)μmol/L和低切粘度(11.02±2.3)均高于A组,有显著性差异(P〈0.05-〈0.01)。结论:T2DM和高血压病均可导致血脂代谢异常,微血管损害和血液流变学的改变,当T2DM合并高血压时,前述异常和损害加重,应及早控制。
简介:目的对中西医结合治疗在2型糖尿病患者中的治疗方式进行讨论。方法选取我院2013年2月-2014年2月间64例2型糖尿病患者,将其分为两组,1组进行常规治疗,2组在进行常规治疗的同时配合中药治疗,对两组患者的治疗效果进行比较。结果1组患者治疗后效果显著的为13例,占比例的40.6%,治疗有效的为14例,占比例的43.8%,治疗无效的患者为5例,占比例的15.6%。2组患者治疗效果显著的为23例,占比例的71.9%,治疗有效的为8例,占比例的25%,治疗无效的仅为1例,占比例的3.1%。结论中西医结合方式治疗2型糖尿病的效果显著,且安全性高,是一种值得推广的治疗方式。
简介:ObjectivesToevaluateantihypertensiveefficiencyandsafetyofanewdomesticofL-&N-typeCa^2+antagonist-eilnidipinewithimidaprilasapositivecontrol.MethodsAfter2weeks'placebowashingout,22patientsweretreatedwitheilnidipine5mgdailyand27patientsweretreatedwithimidapril5mgdaily.4weekslater,ifpatient'ssittingdiastolicbloodpressureisover90mmHg,his/herdosagewasdoubledforanother4weeks,theothersmeasuringupremainedtheirdosageunchangedforanother4weeks.Bloodpressure,heartrate,bloodandurineroutineexamination,serumglucose,serumchemicalexaminationincludingtotalcholesterol,triglyceride,HDL,LDL,transaminase,creatineetcandsidereactionswererecordedbeforeandafterthetrial.Datawereanalyzedstatistically.ResultsAfter8weeks'treatment,bloodpressurewassignificantlydecreased(P<0.05)inbothgroups,andthetwomedicineshadsimilarantihypertensiveeffects.Furthermore,thereducingofheartratewasstatisticallysignificantcomparedwithbaseline(P<0.01)inthecilnidipinegroup,butnotintheimidaprilgroup.Thenegativechronotropiceffectofcilnidipinehadlittleeffectoncontinuingthetherapy.Therewerenochangesonbloodandurineroutineexaminationandserumlipid,serumglucose,creatine,transaminaseandetcinbothgroups.Theirsidereactionsweremildandwell-tolerated.ConclusionsCilnidipinehasacon-vincingantihypertensiveeffectsimilartothatofimi-dapril.Especiallycilnidipinemaybeadministeredtopatientswithrelativelymildtachycardia.
简介:BackgroundAldosteroneblockerscouldreducetheincidenceofventriculararrhythmiasinmyocardialinfarction(MI)patientsbyregulatinghyperpolarization-activatedcyclicnucleotide-gatedchannel(HCN)expression.ButthemechanismunderlingHCNexpressionisunclear.MethodsEighteenratssurviving24hourspostMIwererandomlydividedinto3groups:MI,spironolactone,andspironolactone+antagomir-133(miRNA-133suppression).Shamgroupratshadasuturelooselytiedaroundtheleftcoronaryartery,withoutligation.HCN2andHCN4proteinandmRNAlevel,andmiRNA-133levelintheborderzoneofpost-MI1weekmyocardiumweremeasured.ResultsSpironolactonesignificantlyincreasedmiRNA-133levelsanddown-regulatedHCN2andHCN4atbothmRNAandproteinlevelsinpost-MIborderzonemyocardium.Antagomir-133reducedtheeffectsofspironolactoneonHCN2andHCN4proteinlevels.ConclusionsTheresultssuggestthatmiRNA-133isinvolvedinspironolactoneinducedHCNexpression,andpartiallycontributedtopost-MIventriculararrhythmias.